

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DHB

Date	1.12.99
Time	1.13
Certifier	CWMS DAY

Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 29, 1999, 8:30 a.m. to 6:30 p.m.

Location: Holiday Inn, Versailles Ballrooms III and IV, 8120 Wisconsin Ave., Bethesda, MD.


Contact Person: Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will: (1) Discuss the influenza virus vaccine formulation for 1999 and 2000, and (2) hear an update on the status of influenza A H5N1 viruses.

Procedure: On January 29, 1999, from 8:30 a.m. to 5:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 22, 1999. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:15 a.m., and between 3:30 p.m. and 4 p.m. Time allotted for each presentation may be

limited. Those desiring to make formal oral presentations should notify the contact person before January 22, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 29, 1999, from 5:30 p.m. to 6:30 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). This portion of the meeting will be closed to discuss issues relating to pending or proposed investigational new drug applications.



Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 7, 1999

:


MA Friedman

Michael A. Friedman
Deputy Commissioner for Operations

[FR Doc. 98-???? Filed ??-??-98; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

A large, stylized handwritten signature in black ink, appearing to be 'M. Friedman', is written over the certification text.